Gilberto de Castro

Instituto do Câncer do Estado de São Paulo ORCID: 0000-0001-8765-3044

3

h-index

6

Publications

21,512

Citations

Publications

3 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

2019 The Lancet 2928 citations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst , Paul Baas , Dong‐Wan Kim +16 more

2015 The Lancet 6378 citations

Frequent Co-Authors

Tony Mok

Chinese University of Hong Kong

Yi‐Long Wu

Guangdong Provincial People's Hospital

Iveta Kudaba

Riga East University Hospital

Dariusz M. Kowalski

Université Toulouse III - Paul Sabatier

Byoung Chul Cho

Yonsei University

H.Z. Turna

Istanbul University

Researcher Info

h-index: 3
Publications: 6
Citations: 21,512
Institution: Instituto do Câncer do Estado de São Paulo

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-8765-3044

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.